Spectral Medical Inc. (SD4.SG)
Chart Events
Performance Outlook
| Previous Close | 0.2140 |
| Open | 0.2160 |
| Bid | 0.2160 x 0 |
| Ask | 0.2420 x 0 |
| Day's Range | 0.2160 - 0.2160 |
| 52 Week Range | 0.1740 - 0.4200 |
| Volume | |
| Avg. Volume | 10 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Mar 22, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Spectral Medical Provides Update on Tigris Clinical Trial and Other Business Developments
50 Patients Randomized to Date out of the 150 Total Target to be Enrolled Reports Significant Uptick in Screening and Enrollment Activities TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided a business update focusing on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which
- Simply Wall St.
When Can We Expect A Profit From Spectral Medical Inc. (TSE:EDT)?
We feel now is a pretty good time to analyse Spectral Medical Inc.'s ( TSE:EDT ) business as it appears the company may...
- GlobeNewswire
Spectral Medical Announces Strategic Joint Venture With Infomed to Accelerate Commercialization of Dimi and Sami Dialysis Devices
Spectral to receive a significant equity stake in the joint venture, while eliminating its need to fund future capital requirements for SAMI and DIMITORONTO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical
